The management of the hyperlipidaemias
The hyperlipidaemias are a common and heterogeneous group of metabolic disorders which affect more than 10% of the population of Western industrialized countries [1–3]. Although hypertension and diabetes mellitus are well established as predisposing factors for the development of atherosclerotic disease [4, 5] the role of dietary fat and altered lipoprotein metabolism is not so well understood [6–8]. Epidemiological studies have demonstrated that increased levels of plasma cholesterol may be associated with premature coronary heart disease [2, 3] and the United States Lipid Research Clinics trial  has given clear evidence that reducing high cholesterol levels in men will lower the incidence of coronary heart disease (CHD), and additionally will significantly reduce deaths, myocardial infarcts, angina and the need for coronary artery bypass surgery. These results confirm previous similar reports [10–12].
KeywordsCoronary Heart Disease Bile Acid Nicotinic Acid Familial Hypercholesterolaemia Bile Acid Sequestrant
Unable to display preview. Download preview PDF.
- 1.Carlson, L.A. and Linstedt, S. (1969) The Stockholm Prospective Study. The initial values for plasma lipids. Acta Med. Scand., Suppl., 493.Google Scholar
- 4.Marks, H.H., Krall, L.P. and White, P. (1971) Epidemiology and detection of diabetes mellitus. In Joslin’s Diabetes Mellitus (ed. Marble, White, Bradley and Krall), Lea and Febiger, Philadelphia.Google Scholar
- 10.Dayton, S., Pearce, M.L., Hashimoto, S. et al. (1969) A controlled trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation, 40, (Suppl. 2), 1.Google Scholar
- 17.Gensini, G.G., Esente, P. and Kelly, A. (1974) Natural history of coronary disease in patients with and without coronary bypass graft surgery. Circulation, 50, 98.Google Scholar
- 19.Galton, D.J., Stocks, J. and Dodson, P.M. (1982) Lipoproteins - their role in enzyme regulation. In Clinical Biochemistry Review, Vol. 3. (ed. D.M. Golberg) Wiley, New York.Google Scholar
- 20.Beaumont, J.L., Carlson, L.A., C000per, G.R. et al. (1970) Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull. Wld. Hlth, Org., 43, 891.Google Scholar
- 21.Fredrickson, D.S., Goldstein, J.L. and Brown, M.S. (1983) in The Metabolic Basis of Inherited Disease, 5th edn, (eds J.B. Stanbury, J.B. Wyngaarden, & D.S. Fredrickson). McGraw-Hill, New York.Google Scholar
- 22.Lewis, B., Chait, A., Wootton, I.D.P. et al. (1974) Frequency of risk factors in a healthy British population. Lancet, i, 141.Google Scholar
- 29.Committee of Principal Investigators (1980) WHO cooperative trial on the prevention of ischaemic heart disease using clofibrate to lower serum cholesterol. Mortality follow-up. Lancet, 11, 379.Google Scholar
- 34.Witztum, J.L., Schonfield, D. and Weidman, S.W. (1976) The effect of colestipol on the metabolism of very low density lipoproteins in man. J. Lab. Clin. Med., 88, 108.Google Scholar
- 36.Levy, R.L., Fredrickson, D.S., Kwiterovich, P.O. et al. (1969) Normalisation of lipids in familial hypercholesterolaemia. Circulation, 40, (Suppl.3), 15.Google Scholar
- 38.Buchwald, H., Moore, R.B. and Varco, R.L. (1981) in Atherosclerosis V (eds A.M. Gotto et al.), Springer-Verlag, Berlin, pp. 462–5.Google Scholar